Psilocin suppresses methamphetamine‐induced hyperlocomotion and acquisition of conditioned place preference via D2R‐mediated ERK signaling

Psilocin is an active metabolite form of psilocybin and exerts psychoactive effects. Recent studies suggest that psilocin may have regulatory effects on abuse drugs, but the mechanisms remain unclear. In this study, we want to explore the effects of psilocin on methamphetamine (METH)‐induced alterations of behavior in mice and its molecular mechanisms.

[1]  Q. Lei,et al.  Betahistine alleviates benign paroxysmal positional vertigo (BPPV) through inducing production of multiple CTRP family members and activating the ERK1/2-AKT/PPARy pathway , 2022, Biological Research.

[2]  Pei-Chun Chen,et al.  Inhibitory Effects of Trifluoperazine on Peripheral Proinflammatory Cytokine Expression and Hypothalamic Microglia Activation in Obese Mice Induced by Chronic Feeding With High-Fat-Diet , 2021, Frontiers in Cellular Neuroscience.

[3]  M. Mikuła,et al.  Selective Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibition by the SCH772984 Compound Attenuates In Vitro and In Vivo Inflammatory Responses and Prolongs Survival in Murine Sepsis Models , 2021, International journal of molecular sciences.

[4]  J. Travers,et al.  p38 MAP-kinase inhibitor protects against platelet-activating factor-induced death in mice. , 2019, Free radical biology & medicine.

[5]  Xu-Feng Huang,et al.  Aripiprazole and haloperidol protect neurite lesions via reducing excessive D2R-DISC1 complex formation , 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[6]  M. Motevalian,et al.  Protective role of metformin against methamphetamine induced anxiety, depression, cognition impairment and neurodegeneration in rat: The role of CREB/BDNF and Akt/GSK3 signaling pathways. , 2019, Neurotoxicology.

[7]  C. Svarer,et al.  Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels , 2019, Neuropsychopharmacology.

[8]  Elizabeth M. Nielson,et al.  The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions , 2018, Front. Pharmacol..

[9]  S. Katsurabayashi,et al.  The antipsychotic trifluoperazine reduces marble-burying behavior in mice via D2 and 5-HT2A receptors: Implications for obsessive–compulsive disorder , 2018, Pharmacology Biochemistry and Behavior.

[10]  J. Homberg,et al.  Psilocybin for treating substance use disorders? , 2017, Expert review of neurotherapeutics.

[11]  R. Dinis-Oliveira.  Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance , 2017, Drug metabolism reviews.

[12]  Matthew W. Johnson,et al.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial , 2016, Journal of psychopharmacology.

[13]  Milky Kohno,et al.  Chronic methamphetamine abuse and corticostriatal deficits revealed by neuroimaging , 2015, Brain Research.

[14]  H. Sun,et al.  The brain gene expression profile of dopamine D2/D3 receptors and associated signaling proteins following amphetamine self-administration , 2015, Neuroscience.

[15]  Heinrich J.G. Matthies,et al.  mTORC2/Rictor Signaling Disrupts Dopamine-Dependent Behaviors via Defects in Striatal Dopamine Neurotransmission , 2015, The Journal of Neuroscience.

[16]  A. Christopoulos,et al.  Proof of concept study for designed multiple ligands targeting the dopamine D2, serotonin 5-HT2A, and muscarinic M1 acetylcholine receptors. , 2015, Journal of medicinal chemistry.

[17]  R. Strassman,et al.  Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study , 2015, Journal of psychopharmacology.

[18]  M. Laorden,et al.  Acute Morphine, Chronic Morphine, and Morphine Withdrawal Differently Affect Pleiotrophin, Midkine, and Receptor Protein Tyrosine Phosphatase β/ζ Regulation in the Ventral Tegmental Area , 2015, Molecular Neurobiology.

[19]  A. Nitta,et al.  Knockdown of Dopamine D2 Receptors in the Nucleus Accumbens Core Suppresses Methamphetamine-Induced Behaviors and Signal Transduction in Mice , 2015, The international journal of neuropsychopharmacology.

[20]  Matthew W. Johnson,et al.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction , 2014, Journal of psychopharmacology.

[21]  S. Knapp,et al.  A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics , 2014, Nature chemical biology.

[22]  Tomas Palenicek,et al.  The Effect of Psilocin on Memory Acquisition, Retrieval, and Consolidation in the Rat , 2014, Front. Behav. Neurosci..

[23]  K. Fuxe,et al.  Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes. , 2014, Biochemical and biophysical research communications.

[24]  T. Nabeshima,et al.  Galantamine attenuates reinstatement of cue‐induced methamphetamine‐seeking behavior in mice , 2014, Addiction biology.

[25]  S. Lammel,et al.  Projection-Specific Modulation of Dopamine Neuron Synapses by Aversive and Rewarding Stimuli , 2011, Neuron.

[26]  Wim van den Brink,et al.  Harm potential of magic mushroom use: a review. , 2011, Regulatory toxicology and pharmacology : RTP.

[27]  S. Kędracka-Krok,et al.  Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors. , 2010, Biochimica et biophysica acta.

[28]  K. Fuxe,et al.  Dopamine D2 and 5-hydroxytryptamine 5-HT(₂A) receptors assemble into functionally interacting heteromers. , 2010, Biochemical and biophysical research communications.

[29]  A. Grace,et al.  Cortico-Basal Ganglia Reward Network: Microcircuitry , 2010, Neuropsychopharmacology.

[30]  E. Stein,et al.  A single high dose of methamphetamine increases cocaine self-administration by depletion of striatal dopamine in rats , 2009, Neuroscience.

[31]  J. Cadet,et al.  Methamphetamine toxicity and messengers of death , 2009, Brain Research Reviews.

[32]  S. Schiffmann,et al.  D2R striatopallidal neurons inhibit both locomotor and drug reward processes , 2009, Nature Neuroscience.

[33]  R. Griffiths,et al.  Human hallucinogen research: guidelines for safety , 2008, Journal of psychopharmacology.

[34]  J. Javitch,et al.  D2 Receptors Regulate Dopamine Transporter Function via an Extracellular Signal-Regulated Kinases 1 and 2-Dependent and Phosphoinositide 3 Kinase-Independent Mechanism , 2007, Molecular Pharmacology.

[35]  H. Meziane,et al.  Absence of dopamine D2 receptors unmasks an inhibitory control over the brain circuitries activated by cocaine , 2007, Proceedings of the National Academy of Sciences.

[36]  T. Sotnikova,et al.  An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior , 2005, Cell.

[37]  D. Self.  Regulation of drug-taking and -seeking behaviors by neuroadaptations in the mesolimbic dopamine system , 2004, Neuropharmacology.

[38]  N. Volkow,et al.  Drug addiction: the neurobiology of behaviour gone awry , 2004, Nature Reviews Neuroscience.

[39]  T. Sotnikova,et al.  Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  B. Soares,et al.  Trifluoperazine for schizophrenia. , 2004, The Cochrane database of systematic reviews.

[41]  B. Roques,et al.  Importance of ERK activation in behavioral and biochemical effects induced by MDMA in mice , 2003, British journal of pharmacology.

[42]  Peter Vontobel,et al.  5-HT Modulation of Dopamine Release in Basal Ganglia in Psilocybin-Induced Psychosis in Man—A PET Study with [11C]raclopride , 1999, Neuropsychopharmacology.

[43]  G. Aghajanian,et al.  The role of serotonin in the pathophysiology and treatment of schizophrenia. , 1997, The Journal of neuropsychiatry and clinical neurosciences.

[44]  J. Davies,et al.  The involvement of 5‐hydroxytryptamine in the release of dendritic dopamine from slices of rat substantia nigra , 1983, The Journal of pharmacy and pharmacology.

[45]  C. Marsden,et al.  Serotoninergic modulation of the dopamine response from the nucleus accumbens , 1976, The Journal of pharmacy and pharmacology.

[46]  G. Milner.  The effect of antidepressants and “tranquillizers” on the response of mice to ethanol , 1968, British journal of pharmacology.